Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just a re-iteration of progress and positive moves forward.
Phase 3 Trial Currently Underway
“Right now, there's a lot of interest in treatments,” said CEO Michael Frank by phone. “Vaccines are not necessarily here tomorrow. This virus comes with a lot of side effects, and the drug we have has a strong history and safety profile.”
The drug in question, bucillamine, is an anti-rheumatic, anti-inflammatory drug that has been used in Japan and South Korea to treat rheumatoid arthritis for more than 30 years. According to Frank, Revive repurposed the drug for the first time in 2015 and 2016 during a phase two clinical trial for gout. It is now being repurposed once again to target inflammation of the lungs caused by the virus. Revive is the only company currently studying the drug for this use, and expects to share preliminary data once analyzed, after the 210 interim patient point is reached.
In July, the company received approval from the U.S. Food and Drug Administration to conduct a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the safety and efficacy of the drug in patients with mild to moderate cases of Covid-19.
Nice write up....
Another company that has taken a strong interest in this category is Revive Therapeutics. The Toronto based company is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol to treat auto immune hepatitis and reperfusion injury from organ transplantation.
What does all of this mean? It means more and more companies like Revive are understanding there’s a need to help these fighters that are dealing with brain issues long after they’re done fighting.
Hopefully it's a platform for further positive advances.
Long and Strong for IPIX!
Just a quick re-iteration of all the good going on with this "diamond on the rough" sort of opportunity.
“Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Fast Track designation is well-timed, as we anticipate starting our Phase 2 clinical trial in hospitalized COVID-19 patients this month, and should help bring Brilacidin to patients faster in these dire times.”
Long and Strong
3BB
I hope you mean 2021! LOL
Paragraph from MicroDaily write up back in Sept 2020.
Currently running northbound in a hurry RNWF is an exciting story developing in small caps; Revers Merger plays (RM) are the hottest ticket in penny stocks responsible for many of the biggest winners in recent years. RMWF seems to be the perfect candidate; a clean shell, no debt, no dilution (OS has not increased in years) and management has stated many times no reverse coming. Big things have been happening behind the scenes as the Company became “pink current” on June 15 when the CE was removed. The Company has also set up the website for the incoming merger here: http://www.rnwfmerger.com as well as created a new twitter account. Justin Costello who has operated many successful MJ companies in the past has come up. RNWF CEO’s LinkedIn page also gives us some preliminary general indicators on the possible nature of operations that Krisa Management, LLC may bring into RNWF. We will be updating on RNWF when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RNWF.
Tremendous volume today!
Appreciate it....Thank you!
Are you in both HPST and RNWF?
Last twitter tweet Aug 6th, 2020.
https://twitter.com/RnwfMerger/status/1291434372583903233?s=20
Fisker Stock Is On Track To Double Over the Next Year or So
Mark R. Hake, InvestorPlace
Dec. 31, 2020, 10:31 AM
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Now that Fisker (NYSE:FSR) has signed a definitive agreement with Magna International (NYSE:MGA) to make its new Ocean electric SUV, I took another look as what I wrote about this earlier in December. I believe that analysis still stands especially now that the Magna deal is finalized. And, I still believe Fisker stock is likely worth between $26 and $30.
Source: Eric Broder Van Dyke / Shutterstock.com
Fisker says it now has all the money it needs to start producing the Ocean SUV by Q4 2022.
In other words, it won’t need to raise any more capital that would dilute existing shareholders.
With the proceeds of warrant sales that I covered in my Dec. 15 article, shareholders will be diluted once all the holders exercise their warrants to buy shares. I estimate the extra capital raised will dilute shareholders by about 9% or so.
The company received $1 billion from the merger and now it will have an additional $261 million. That $1.26 billion acts to lower its enterprise value (EV) and valuation, as I show below.
Fisker Stock Valuation
The basis for my optimism about Fisker stock is its valuation comparison with other EV shares. For example, I showed in my previous article that Fisker stock trades for just 2.34 times its adjusted EBITDA in 2025.
Here is how that works. Fisker’s market capitalization is now about $4.52 billion at a price of $15.40 on Dec. 29. After deducting $1.26 billion in cash, including the exercise of warrants, the enterprise value is $3.26 billion.
Grading 10 of 2020's Hottest SPACs in Preparation for the New Year
Moreover, its 2025 EBITDA is forecast to be $2.8 billion. I estimate this is worth a lower amount, about 50%, or $1.392 billion, on a present value basis. I used a 15% discount rate to derive that EBITDA number.
Therefore, the enterprise-to-EBITDA number today is just 2.34x. This is found by dividing the enterprise value (EV) of $3.26 billion by the adjusted present value 2025 EBITDA of $1.392 billion.
This seems to me to be way too low a valuation. As I wrote last time, the stock is likely to move up to a 5-6x EV-to-EBITDA multiple.
For example, at 5.5 times its EBITDA, the enterprise value would be $7.656 billion (i.e., $5.5x $1.392 billion). Moreover, to get the market cap we add back the $1.26 billion in cash. That implies its market cap should be $8.9 billion, instead of $4.52 billion today.
This means that Fisker stock should be 100% higher. Its $8.9 billion market cap valuation is 97% above the existing $4.52 billion market cap today.
And of course, if we used 6x as a multiple, the implied market cap would be $9.6 billion. That is 112% above the present market cap.
In other words, Fisker stock is worth between $30.38 and $32.75 per share (i.e., 97-112% above today’s price).
What To Do With FSR Stock
Other analysts are now beginning to value FSR stock higher than its price today. For example, Tipranks shows that Fisker stock has four analysts who cover the stock. Their average target price is $19.75 a share.
This represents a potential gain of 28.2% above the Dec. 29 price of $15.40 per share. This is also the same price target that Yahoo! Finance reports on Fisker stock.
Moreover, Marketbeat shows five analysts cover Fisker stock, with a consensus target price of $21 per share. This represents a potential gain of 36% above today’s price.
Therefore, given our analysis that Fisker stock is worth at least twice its price and others’ projections, it seems Fisker stock is undervalued.
This is also where Barron’s sees the stock. The magazine wrote in early November that Cowen analyst Jeffrey Osborne believes the stock is worth $22 per share.
So, it seems just about everybody likes Fisker stock. We all think it is bound to move higher. That probably bodes well for its near term future over the next year.
On the date of publication, Mark R. Hake did not hold a long or short position (either directly or indirectly) in any stock mentioned in this article.
Mark Hake runs the Total Yield Value Guide which you can review here.
Thank you Bobby....appreciate it.
Any links here to the new research happenings with glass battery?
I'm new to this company....Is this part of the quantum glass battery opportunity?
TIA
3BB
Yes very nice....looking at adding addition 350,000 more
Parallel cannabis CEO currently talking on 2021 on Squawk
Yes...Happy New Year everyone...2021 has great things in store. Wishing everyone much success, peace and family love for 2021!
Yes...Happy New Year everyone...2021 has great things in store. WIshing everyone much success, peace and family love for 2021!
Good morning Passs....agree with you on the 2021/2022 fsr opportunities. If you don't mind me asking....what is "your company"?
TIA
3BB
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study
7:00 AM ET 12/31/20 | GlobeNewswire
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study
TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the Company to assist in the expansion and the analysis of the clinical data on the ongoing U.S. Food & Drug Administration ("FDA") Phase 3 clinical trial (the "Study") to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
Dr. Fahy is the author of a recently published study, titled "Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry" showing that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. The findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provide rationale to test thiol-based drugs as novel treatments for COVID-19.
Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than N-acetyl-cysteine. Bucillamine has a well-known safety profile with over 30 years of use as a treatment for rheumatoid arthritis in Japan and South Korea.
"Dr. Fahy is a distinguished clinical researcher with thiol-based drugs, such as Bucillamine, and his understanding of its mechanism of action and how it relates to SARS-CoV-2 will be valuable in assessing our interim analysis of our FDA Phase 3 study," said Michael Frank, CEO of Revive.
Dr. Fahy stated: "I look forward to serving as a scientific and clinical advisor to Revive to evaluate the utility of Bucillamine as a novel treatment for COVID-19."
Dr. John Fahy, MD, MSc is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California San Francisco and is a director of UCSF's severe asthma clinic. He also cares for critically ill patients in the intensive care units and directs the UCSF Airway Clinical Research Center. His research receives funding from the National Institutes of Health and various foundations, as well as contracts from biotechnology and pharmaceutical companies in disease mechanisms of asthma, cystic fibrosis and other airway diseases. Fahy earned his medical degree at the University College Dublin. After internal medicine training in Dublin, he completed fellowship training in pulmonary and critical care medicine at UCSF. He is the Michael S. Stulbarg Endowed Chair in Pulmonary Medicine.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Just checked in for the day....what's going on? I don't see any news posted but I haven't dug either. Just checked yahoo, etrade and ihub.
TIA
3BB
Craziness!!
Why did someone just sell 1,000,000 shares at .0048 when right before that were buys at .0059?
TIA
Good morning!
Ditto...welcome back!
God bless and Happy Holidays!
Ahhhh...thank you kindly!
My bad...but what/who is PIPE?
TIA
3BB
OT: Beautiful tree! Thank you for sharing the beauty.
Merry Christmas!
3BB
Excellent news!
Nicely put Boon
Nice 80k block buy at .41
Ditto!
Nice volume in the first 25 minutes of trading....more than 600 shares thus far.
Thank you for excellent data
Thank you.
We are about to have some movement.
https://finance.yahoo.com/news/7-telehealth-stocks-buy-ahead-174457734.html
Just added to the radar
GLTY
3bb
What about on ETRADE? Thank you in advance!
Apologies my response was not intended to be ?? I tried to send a thumbs up sign back to you.
Have any of you even looked at the trades for the day? Last trade was at 1:57 for 1000 shares at .0019
Entire day are sells. No ones buying js.